LMR Partners LLP acquired a new stake in Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 29,793 shares of the company’s stock, valued at approximately $2,276,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Martingale Asset Management L P boosted its position in shares of Merck & Co., Inc. by 0.7% in the 3rd quarter. Martingale Asset Management L P now owns 694,680 shares of the company’s stock valued at $49,281,000 after purchasing an additional 5,121 shares during the period. Laurel Wealth Advisors Inc. boosted its position in shares of Merck & Co., Inc. by 5.0% in the 3rd quarter. Laurel Wealth Advisors Inc. now owns 32,332 shares of the company’s stock valued at $2,293,000 after purchasing an additional 1,531 shares during the period. AQR Capital Management LLC boosted its position in shares of Merck & Co., Inc. by 27.7% in the 3rd quarter. AQR Capital Management LLC now owns 8,288,273 shares of the company’s stock valued at $587,970,000 after purchasing an additional 1,796,360 shares during the period. Resources Management Corp CT ADV acquired a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at about $1,396,000. Finally, Greenwood Gearhart Inc. boosted its position in shares of Merck & Co., Inc. by 2.3% in the 3rd quarter. Greenwood Gearhart Inc. now owns 121,609 shares of the company’s stock valued at $8,627,000 after purchasing an additional 2,707 shares during the period. 72.57% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on the company. Atlantic Securities raised Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a research report on Monday, May 13th. They noted that the move was a valuation call. ValuEngine raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. UBS Group upped their target price on Merck & Co., Inc. from $87.00 to $88.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Bank of America upped their target price on Merck & Co., Inc. from $90.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, BMO Capital Markets upped their target price on Merck & Co., Inc. from $83.00 to $84.00 and gave the company a “market perform” rating in a research report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average price target of $82.92.

In other Merck & Co., Inc. news, major shareholder Merck & Co., Inc. bought 4,121,683 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was acquired at an average cost of $16.00 per share, with a total value of $65,946,928.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Robert M. Davis sold 192,572 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $82.38, for a total value of $15,864,081.36. Following the transaction, the executive vice president now directly owns 330,232 shares of the company’s stock, valued at $27,204,512.16. The disclosure for this sale can be found here. Insiders have sold a total of 538,099 shares of company stock valued at $43,923,339 over the last ninety days. 0.27% of the stock is owned by insiders.

Merck & Co., Inc. stock opened at $80.98 on Thursday. Merck & Co., Inc. has a twelve month low of $58.03 and a twelve month high of $83.85. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 0.82. The company has a market cap of $214.35 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 1.88 and a beta of 0.58.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.17. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The company had revenue of $10.82 billion during the quarter, compared to analysts’ expectations of $10.45 billion. During the same period last year, the firm earned $1.05 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, research analysts forecast that Merck & Co., Inc. will post 4.72 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “LMR Partners LLP Takes $2.28 Million Position in Merck & Co., Inc. (MRK)” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2019/05/23/lmr-partners-llp-takes-2-28-million-position-in-merck-co-inc-mrk.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: What are the reasons investors use put options?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.